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t is often said that leading drug 
companies now spend more 
on marketing than on research 
and development [1]. While such 
contemporary pharmaceutical 
marketing practices are sometimes 
believed to be a modern phenomenon, 
they are in fact a direct continuation 
of 19th-century patent medicine 
advertising. “Nostrum-mongers,” as the 
novelist Henry James dubbed them, 
are noted in the history of advertising 
as having been the leading spenders 
on, and foremost originators of, 
advertising technique [2,3]. Nostrum 
sellers pioneered print advertising, 
use of trademarks and distinctive 
packaging, “pull” or demand-
stimulation strategies, and even the 
design and commissioning of medical 
almanacs that functioned as vehicles for 
promotion of disease awareness. Henry 
James’s psychologist brother, William 
James, was so exasperated by “the 
medical advertisement abomination” 
that in 1894 he declared that “the 
authors of these advertisements should 
be treated as public enemies and have 
no mercy shown” (see page 235 in [4]). 
    There is no doubt that drug 
company discoveries have profoundly 
improved upon our capacity to treat 
illness. But pharmaceutical marketing 
is more closely aligned with consumer 
marketing in other industries 
than with medicine, for which the 
consequences are not trivial. Once we 
view pharmaceutical industry activities 
in this light, we can disentangle 
industry’s inﬂ  uence on contemporary 
medicine. Because we believe that 
we owe corporations our wealth and 
well-being, we tend not to question 
corporations’ fundamental practices, 
and they become invisible to us. What 
follows is an attempt to demystify some 
of the assumptions at work in the 
“culture of marketing,” toward the goal 
of explaining contemporary disease 
mongering. 
    Beliefs about the Free Market
    There are three beliefs commonly 
associated with the “free market.” The 
ﬁ  rst is that human beings are creatures 
of limitless but insatiable needs, wants, 
and discomforts. The second is that 
the free market is a place where these 
needs might be satisﬁ  ed through the 
exercise of free choice. The last of 
these beliefs is that the surest avenue 
to innovation in all industries is 
unfettered competition in the market. 
      Insatiable needs.   The anthropologist 
Marshall Sahlins theorizes that the 
belief in unlimited wants is unique in 
the West, and stems from the Christian 
notion of “fallen man” as sufferer. 
This results, says Sahlins, in a peculiar 
idea of the person “as an imperfect 
creature of need and desire, whose 
whole earthly existence can be reduced 
to the pursuit of bodily pleasure and 
the avoidance of pain” [5]. A historical 
and philosophical examination of 
professional marketing shows that an 
assumption of boundless needs and 
wants is also at the heart of marketing 
theory. In this sense, marketing can 
be regarded as the institutionalization 
of this view of human nature. The 
marketer’s challenge is to translate 
those limitless needs into proﬁ  ts.
    Sahlins also points out that “in 
the world’s richest societies, the 
subjective experience of lack increases 
in proportion to the objective output 
of wealth” [6]. In other words, the 
richer we get, the more we want. 
One explanation of this paradox lies 
in the way marketing activities are 
instrumental in getting us to think 
more about what we lack. Marketers 
and advertisers project and reﬂ  ect back 
to us our discontent with the status 
quo. Americans are said to spend, 
on average, three years of their lives 
watching television advertisements, and 
the effect is that they are conditioned 
to want more and more. According 
to the advertisements, the viewer’s 
personal anxieties and dissatisfactions 
are best addressed by consumption. 
This same message lies at the heart of 
much pharmaceutical advertising. 
      Lifestyle choices.   In a consumer 
society, when individuals make choices 
toward the satisfaction of their needs 
and wants, they experience this as 
constructing their own individuality 
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and identity. This special consumer 
identity is what people refer to when 
they use the word lifestyle, though 
they may not realize the consumerist 
implications of the word. Marketing 
claims to provide a solution to the 
problem of unlimited needs and wants, 
while simultaneously enhancing free 
choice and the construction of lifestyle.
    In pharmaceuticals speciﬁ  cally, 
“lifestyle drug” marketing techniques 
were honed in the 1980s and 1990s for 
cosmetic and sexual enhancements 
[7,8]. These techniques have been 
broadened to include other areas 
of medicine. The campaigns used 
to market cosmetic and sexual 
enhancements were focused on 
expanding perceived need for these 
products, and in this respect were 
a simple extension of customary 
marketing conduct that had existed 
for over half a century. The crossover 
to curative medicine occurred with 
psychotropic drugs, which have a very 
wide range of active properties, thus 
granting the marketer latitude in 
reinterpreting their value back to the 
consumer. For example, one class of 
antidepressants, the speciﬁ  c serotonin 
reuptake inhibitors, is marketed for 
eight distinct psychiatric conditions, 
ranging from social anxiety disorder 
to obsessive-compulsive disorder to 
premenstrual dysphoric disorder. 
And “lifestyle marketing” has now 
extended to the promotion of many 
of the blockbuster “maintenance 
drugs” intended for daily, lifelong 
consumption, such as drugs for 
allergies, insomnia, and acid reﬂ  ux.
    As a result of this sequence of 
events, industry opened the treatment 
of the inside of the body—the ﬁ  nal 
frontier—to the same logic that 
governs all other marketing. Whether, 
in the antidepressant market, the 
“distribution channel captain,” as 
marketers refer to the predominant 
competitor, ends up sailing the 
serotonin reuptake channel (the 
serotonin reuptake inhibitors) or the 
norepinephrine reuptake channel (the 
challenger, serotonin–norepinephrine 
reuptake inhibitors) may yet be 
determined by marketing rather than 
by medical jockeying. 
      Competition among drug companies 
yields innovation.   It is an article of 
faith among free market devotees 
that breakthroughs spring not from 
paternalistic expert systems such 
as medicine but from industrial 
competition. As long as ﬁ  rms are 
committed to producing medications 
to treat diseases—as they are 
classiﬁ  ed by medical science—this 
argument has some authority. But 
once a ﬁ  rm becomes principally 
driven by marketing—the case for 
most companies in most industries 
since the 1980s—then innovation 
comes to mean an elaboration of 
meaningless differences among 
a ﬁ  eld of comparable “me too” 
products. “If marketing is seminally 
about anything,” said Theodore 
Levitt, one of the towering ﬁ  gures 
of marketing and former editor of 
the   Harvard Business Review  , “ it is 
about achieving customer-getting 
distinction by differentiating what you 
do and how you operate” [9]. More 
harmfully, expanding and altering 
the consumer’s perception of disease 
is just as effective, and evidently a lot 
easier, than ﬁ  nding new cures. 
    From Patients to Medical 
Consumers
    Since, in a consumer society, we 
see ourselves as individuals and 
as free agents when we exercise 
consumer choice, it is not difﬁ  cult for 
pharmaceutical companies and other 
privatized health-care deliverers to 
convince us that it is empowering to 
think of ourselves not as patients but 
as consumers. This conversion from 
patient to consumer also paves the way 
for the erosion of the doctor’s role as 
expert. A startling report of this was 
described in a recent   New York Times   
article: “For a sizable group of people 
in their 20’s and 30’s, deciding on their 
own what drugs to take—in particular, 
stimulants, antidepressants and other 
psychiatric medications—is becoming 
the norm. Conﬁ  dent of their abilities 
and often skeptical of psychiatrist’s 
expertise, they choose to rely on 
their own research and each other’s 
experience in treating problems like 
depression….A medical degree, in 
their view, is useful but not essential” 
[10]. This phenomenon, the article 
suggested, is “driven by familiarity” 
with the drugs. The emergence of 
this potentially dangerous situation 
demonstrates an unchecked expansion 
of the drug industry into an already 
accepted mode of thought—that “every 
minor mood ﬂ  uctuation,” as the article 
reported, can and should be remedied. 
    Promoting consumer familiarity 
with drugs is one example of the very 
broad inﬂ  uence of the pharmaceutical 
industry. This inﬂ  uence extends to 
clinical trial administration, research 
publication, regulatory lobbying, 
physician and patient education, drug 
pricing, advertising and point-of-use 
promotion, pharmacy distribution, 
drug compliance, and the legal and 
ethical norms by which company 
practices themselves are to be 
evaluated. Actors traditionally found 
outside the “distribution channel” of 
the market are now incorporated into 
it as active proponents of exchange. 
Physicians, academic opinion 
leaders, patient advocacy groups 
and other grass roots movements, 
nongovernmental organizations, 
public health bodies, and even 
ethics overseers, through one means 
or another, have one by one been 
enlisted as vehicles in the distribution 
chain. The inclusion of patients in 
the distribution chain fundamentally 
changes their role from recipients 
of medical care to active consumers 
of the latest pharmaceuticals, a role 
which surely helps to support industry 
proﬁ  ts.
  Ethical  Justiﬁ  cation for Marketing
    Because illness is one of the most 
tangible forms of suffering, the 
pharmaceutical industry, more than 
other industries, can link its marketing 
activities to ethical objectives. The 
result is a marriage of the proﬁ  t-
seeking scheme in which disease is 
regarded as “an opportunity” to the 
ethical view that mankind’s health 
hangs in the balance. Marketers and 
consumers in the West to some extent 
share a common vision of needs and 
the terms of their satisfaction. This 
apparent complicity helps even the 
most aggressive marketers trust that 
they are performing a public service. 
Pharmaceutical company managers 
that I speak to signal this when they 
characterize their engagement with 
the public as “doing good while doing 
well.” 
  An assumption of 
boundless needs and 
wants is at the heart of 
marketing theory. 
April 2006  |  Volume 3  |  Issue 4  |  e189PLoS Medicine  |  www.plosmedicine.org 0447
    These managers also see nothing 
wrong with integrating doctors, 
patients, and other players into 
the drug distribution channel. On 
the contrary, they say, this is state-
of-the-art management, making it 
professionally principled and tactically 
astute. Marketers also regard the 
incorporation of consumers into 
the channel as ethical because then 
people’s needs can best be determined 
and satisﬁ  ed, conferring upon them the 
power of self-determination through 
choice.
    But this choice is an illusion. For in 
our pursuit of a near-utopian promise 
of perfect health, we have, without 
realizing it, given corporate marketers 
free reign to take control of the true 
instruments of our freedom: objectivity 
in science, ethics and fairness in health 
care, and the privilege to endow 
medicine with the autonomy to fulﬁ  ll 
its oath to work for the beneﬁ  t of the 
sick.   
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